TORONTO, April 01, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Profound Medical (PROF) announced the launch of a TULSA program by Texas Prostate and Dallas Medical Center to meet the growing demand for advanced prostate treatment – without surgery. Under the ...

Good morning, everyone. I'm delighted that you have joined us today. Friday, March 13, is a wonderful day. As you know, TULSA is a treatment modality for prostate disease. And although it is a device, ...

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical prostatectomy in an early analysis of a first-ever randomized trial. After 6 months ...

In a randomized trial, half of patients who received TULSA maintained both pad-free continence and erections at 6 months compared with one-quarter who had RP. Magnetic resonance imaging (MRI)-guided ...

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...